SLC6A14 has been identified as a genetic modifier of multiple CF disease outcomes, including meconium ileus (Sun et al., 2012), lung disease (Corvol et al., 2015) and the age of first infection by Pseudomonas aeruginosa (Li et al., 2014). Here, SLC6A14 is linked to Meconium ileus.